Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primary resistance to integrase inhibitors in Shenzhen.

The Journal of antimicrobial chemotherapy - 1 Feb 2023

Zhu Yue, Huang Yuanmei, Zheng Chenli, Tang Jie, Zeng Guang, Xie Wei, Wang Hui, Zhang Lukun, Liu Shaochu, Zhang Yan, Tan Wei, Tan Jingguang, Jiang Lijuan, He Yun, Xu Liumei, Yang Zhengrong, Zhao Jin

Abstract excerpt

OBJECTIVES: In recent years, integrase strand transfer inhibitor (INSTI)-containing regimens have been increasingly adopted in treatment for HIV/AIDS and promoted as non-occupational post-exposure prophylaxis in China. This study aims to describe the prevalence of resistance to integrase and drug resistance mutations (DRMs) among ART-naive patients in Shenzhen, China. METHODS: Serum samples and demographic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Integrases

Share to Pyridones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 36585770
DOI: 10.1093/jac/dkac442

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary resistance to integrase inhibitors in Shenzhen.PMID 36585770Read ↗

Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).Semantic proximity Read ↗

Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, ChinaSemantic proximity Read ↗

Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China.Semantic proximity Read ↗

Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018–2022Semantic proximity Read ↗

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.Semantic proximity Read ↗

Brief communication: characteristics of primary drug resistance in newly diagnosed HIV-infected individuals in Ganzhou, China.Semantic proximity Read ↗

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, ChinaSemantic proximity Read ↗

Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.Semantic proximity Read ↗

Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.Semantic proximity Read ↗

Transmitted HIV-1 Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey.Semantic proximity Read ↗

Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.Semantic proximity Read ↗

Transmitted Drug Resistance Among People Living With HIV-1 in Henan Province, China, 2025Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.